Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03418350 · ClinicalTrials.gov registry record
The Role of Laryngopharyngeal Reflux in IPF
A clinical trial of IPF and Reflux, sponsored by National Jewish Health.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT03418350 is a study of IPF and Reflux that is actively recruiting participants, run by National Jewish Health. The registered enrollment target is 60 participants, below the 275-participant average among 3 other IPF trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03418350, a study of IPF and Reflux, is actively recruiting participants, sponsored by National Jewish Health.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to show that the Supraglottic Index (SGI) is an easily-collected index that accurately identifies the presence and severity of laryngopharyngeal reflux (LPF) in idiopathic pulmonary fibrosis (IPF).
Study Locations (1)
Colorado
- National Jewish Health - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03418350
The ClinicalTrials.gov registry entry for NCT03418350 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 3 other IPF trials with a reported enrollment target (78% lower). The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with IPF appearing as the primary indexed condition, and to 0 interventions.
NCT03418350 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03418350 about?
NCT03418350 is a clinical study titled "The Role of Laryngopharyngeal Reflux in IPF". The primary objective of this study is to show that the Supraglottic Index (SGI) is an easily-collected index that accurately identifies the presence and severity of laryngopharyngeal reflux (LPF) in idiopathic pulmonary fibrosis (IPF).
What is the current status of trial NCT03418350?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2018-08-01. Estimated completion is 2026-12.
What conditions does trial NCT03418350 study?
This clinical trial studies the following conditions: IPF, Reflux.
Who is sponsoring clinical trial NCT03418350?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03418350 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IPF
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.